Circulating insulin-like growth factor I in relation to melanoma risk in the European prospective investigation into cancer and nutrition

Research output: Contribution to journalArticle

Abstract

Insulin-like growth factor-I (IGF-I) regulates cell proliferation and apoptosis, and is thought to play a role in tumour development. Previous prospective studies have shown that higher circulating concentrations of IGF-I are associated with a higher risk of cancers at specific sites, including breast and prostate. No prospective study has examined the association between circulating IGF-I concentrations and melanoma risk. A nested case–control study of 1,221 melanoma cases and 1,221 controls was performed in the European Prospective Investigation into Cancer and Nutrition cohort, a prospective cohort of 520,000 participants recruited from 10 European countries. Conditional logistic regression was used to estimate odds ratios (ORs) for incident melanoma in relation to circulating IGF-I concentrations, measured by immunoassay. Analyses were conditioned on the matching factors and further adjusted for age at blood collection, education, height, BMI, smoking status, alcohol intake, marital status, physical activity and in women only, use of menopausal hormone therapy. There was no significant association between circulating IGF-I concentration and melanoma risk (OR for highest vs lowest fifth = 0.93 [95% confidence interval [CI]: 0.71 to 1.22]). There was no significant heterogeneity in the association between IGF-I concentrations and melanoma risk when subdivided by gender, age at blood collection, BMI, height, age at diagnosis, time between blood collection and diagnosis, or by anatomical site or histological subtype of the tumour (Pheterogeneity≥0.078). We found no evidence for an association between circulating concentrations of IGF-I measured in adulthood and the risk of melanoma.

Details

Authors
  • Kathryn E. Bradbury
  • Paul N. Appleby
  • Sarah J. Tipper
  • Ruth C. Travis
  • Naomi E. Allen
  • Marina Kvaskoff
  • Kim Overvad
  • Anne Tjønneland
  • Jytte Halkjær
  • Iris Cervenka
  • Yahya Mahamat-Saleh
  • Fabrice Bonnet
  • Rudolf Kaaks
  • Renée T. Fortner
  • Heiner Boeing
  • Antonia Trichopoulou
  • Carlo La Vecchia
  • Alexander J. Stratigos
  • Domenico Palli
  • Sara Grioni
  • Giuseppe Matullo
  • Salvatore Panico
  • Rosario Tumino
  • Petra H. Peeters
  • H. Bas Bueno-de-Mesquita
  • Reza Ghiasvand
  • Marit B. Veierød
  • Elisabete Weiderpass
  • Catalina Bonet
  • Elena Molina
  • José M. Huerta
  • Nerea Larrañaga
  • Aurelio Barricarte
  • Susana Merino
  • Ingrid Ljuslinder
  • Oskar Hemmingsson
  • Nick Wareham
  • Kay Tee Khaw
  • Marc J. Gunter
  • Sabina Rinaldi
  • Konstantinos K. Tsilidis
  • Dagfinn Aune
  • Elio Riboli
  • Timothy J. Key
Organisations
External organisations
  • University of Oxford
  • University of Auckland
  • University of Paris-Sud
  • Stabilite genetique et oncogenese
  • Aarhus University
  • Danish Cancer Society Research Center
  • University of Rennes I
  • German Cancer Research Centre
  • German Institute of Human Nutrition
  • Hellenic Health Foundation, Athens
  • University of Milan
  • National and Kapodistrian University of Athens
  • Istituto Nazionale dei Tumori
  • University of Turin
  • University of Naples Federico II
  • Civic and M.P Arezzo Hospital
  • University Medical Center Utrecht
  • Imperial College London
  • University of Malaya
  • National Institute for Public Health and the Environment (RIVM)
  • University of Oslo
  • UiT The Arctic University of Norway, Tromsø
  • Cancer Registry of Norway Institute of Population-Based Cancer Research
  • University of Helsinki
  • Karolinska Institutet
  • Bellvitge University Hospital-IDIBELL
  • University of Granada
  • CIBER Epidemiology and Public Health (CIBERESP)
  • Murcia Regional Health Council
  • Health Research Institute of Navarra (IDISNA)
  • Public Health Directorate
  • Skåne University Hospital
  • Norrland University Hospital
  • Umeå University
  • University of Cambridge
  • International Agency for Research on Cancer, World Health Organization
  • University of Ioannina
  • Bjørknes University College
  • Oslo university hospital
  • Cancer Research and Prevention Institute (ISPO)
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology

Keywords

  • biomarker, EPIC, height, insulin-like growth factor I, melanoma, prospective studies
Original languageEnglish
Pages (from-to)957-966
JournalInternational Journal of Cancer
Volume144
Issue number5
Early online date2018 Sep 7
Publication statusPublished - 2019
Publication categoryResearch
Peer-reviewedYes